About: Arbidol/IFN-α2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Arbidol/IFN-α2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Arbidol/IFN-α2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study
Creator	Xu, Ping Huang, Jianping Fan, Zhao Huang, Wendi Lin, Xuwen Qi, Minghua Song, Weidong
Source	Elsevier; Medline; PMC; WHO
abstract	The spread of COVID-19 is accelerating. At present, there is no specific antiviral drugs for COVID-19 outbreak. This is a multicenter retrospective cohort study of patients with laboratory-confirmed COVID-19 infection pneumonia from 3 hospitals in Hubei and Guangdong province, 141 adults (aged ≥18 years) without ventilation were included. Combined group patients were given Arbidol and IFN-α2b, monotherapy group patients inhaled IFN-α2b for 10-14 days. Of 141 COVID-19 patients, baseline clinical and laboratory characteristics were similar between combined group and monotherapy group, that 30% of the patients leucocytes counts were below the normal range and 36.4% of the patients experienced lymphocytopenia. The duration of viral RNA of respiratory tract in the monotherapy group was not longer than that in the combined therapy group. There was no significant differences between two groups. The absorption of pneumonia in the combined group was faster than that in the monotherapy group. We inferred that Arbidol/IFN - 2b therapy can be used as an effective method to improve the COVID-19 pneumonia of mild patients, although it helpless with accelerating the virus clearance. These results should be verified in a larger prospective randomized environment.
has issue date	2020-05-20(xsd:dateTime)
bibo:doi	10.1016/j.micinf.2020.05.012
bibo:pmid	32445881
has license	no-cc
sha1sum (hex)	c1c4cb5d51bea61374ef83518a90cd4cae81d1f4
schema:url	https://doi.org/10.1016/j.micinf.2020.05.012
resource representing a document's title	Arbidol/IFN-α2b Therapy for Patients With Corona Virus Disease 2019: A Retrospective Multicenter Cohort Study
has PubMed Central identifier	PMC7238991
has PubMed identifier	32445881
schema:publication	Microbes Infect
resource representing a document's body	covid:c1c4cb5d51bea61374ef83518a90cd4cae81d1f4#body_text
is schema:about of	named entity 'Combined' named entity 'counts' named entity 'patients' named entity 'GROUP' named entity 'combined' named entity 'group' named entity 'patients' named entity 'With' named entity 'Arbidol' named entity 'Patients' named entity 'IFN' named entity 'monotherapy' named entity 'leucocytes' named entity 'Corona Virus Disease' named entity 'Corona Virus Disease' named entity 'RT-PCR' named entity 'long time' named entity 'RNA' named entity 'selection bias' named entity 'leucocytes' named entity 'Arbidol' named entity 'zanamivir' named entity 'antiviral therapies' named entity 'pneumonia' named entity 'Arbidol' named entity 'Arbidol' named entity 'viral RNA' named entity 'COVID-19' named entity 'normal range' named entity 'virus' named entity 'monotherapy' named entity 'COVID-19' named entity 'Chest imaging' named entity 'virus' named entity 'chloroquine' named entity 'vaccine' named entity 'pneumonia' named entity 'virus' named entity 'coronavirus' named entity 'Arbidol' named entity 'nucleic acid' named entity 'virus' named entity 'neurogenic bladder' named entity 'antiviral drugs' named entity 'IFN' named entity 'Natural Science' named entity '8 days' named entity 'IFN' named entity 'nucleic acid' named entity 'Interferon-α' named entity 'RNA' named entity 'lymphocytopenia' named entity 'innate immune' named entity 'MERS-coronavirus' named entity 'RT-PCR' named entity 'monotherapy' named entity 'viral RNA' named entity 'cohort study' named entity 'pneumonia' named entity 'CT scan' named entity 'treatment group' named entity 'invasive mechanical ventilation' named entity 'lung inflammation' named entity 'monotherapy' named entity 'lungs' named entity 'respiratory tract' named entity 'exertional dyspnea' named entity 'clinical symptoms' named entity 'Peking University' named entity 'dysuria' named entity 'lung lobes' named entity 'Shenzhen' named entity 'clinical outcome' named entity 'Arbidol' named entity 'SARS-CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software